Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer, Schering Thai units merge (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Bayer Thai Co Ltd and Schering (Bangkok) Ltd are operating under a new name, Bayer Schering Pharma, following the merger of their multinational parent companies. The new division under Bayer Thai Co Ltd continues to focus on research and distribution of pharmaceutical products and aims to be the leading pharmaceutical specialist in Thailand. Bayer Schering Pharma concentrates on women's health care, primary care, diagnostic imaging, and specialty care. The company is currently ranked number eight among multinational pharmaceutical companies in Thailand, and 11th in the overall Thai pharmaceutical market. Bayer Schering expects sales to grow by double digits this year and in the year to come. ''Bayer Schering Pharma is not only committed to continuing to market our current product range that has made us so strong, but to also further expand our portfolio. However, our prime objective is not to be the number one in size; we are instead aiming at leading positions in selected therapeutic areas,'' said Uwe Dalichow, general manager of Bayer Shering Pharma. (Click here for more

You may also be interested in...

Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead

Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.

Strides Readies SteriScience For Injectables Push

Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.

QUOTED. 18 September 2020. Ed Israelski.

The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts